Switching from efavirenz/emtricitabine/tenofovir (EFV/FTC/TDF) or rilpivirine/emtricitabine/tenofovir disoproxil fumarate (RPV/FTC/TDF) to rilpivirine/emtricitabine/tenofovir alafenamide (RPV/FTC/TAF): safety and efficacy through 48 weeks

被引:0
作者
Orkin, C. [1 ]
DeJesus, E. [2 ]
Ramgopal, M. [3 ]
Crofoot, G. [4 ]
Ruane, P. [5 ]
LaMarca, A. [6 ]
Mills, A. [7 ]
Van der Cam, B. [8 ]
De Wet, J. [9 ]
Rockstroh, J. [10 ]
Lazzarin, A. [11 ]
Rijnders, B. [12 ]
Podzamczer, D. [13 ]
Thalme, A. [14 ]
Stoeckle, M. [15 ]
Chu, H. [16 ]
Porter, D. [16 ]
Liu, H. [16 ]
Cheng, A. [16 ]
Quirk, E. [16 ]
SenGupta, D. [16 ]
Cao, H. [16 ]
机构
[1] Barts Hlth NHS Trust, London, England
[2] Orlando Immunol Ctr, Orlando, FL USA
[3] Midway Immunol & Res Ctr, Ft Pierce, FL USA
[4] Crofoot Res Ctr, Houston, TX USA
[5] Peter Jerome Ruane, Los Angeles, CA USA
[6] Therafirst Med Ctr, Ft Lauderdale, FL USA
[7] Mills Clin Res, Los Angeles, CA USA
[8] Clin Univ St Luc, Brussels, Belgium
[9] JJ de Wet, Vancouver, BC, Canada
[10] Bonn Univ Hosp, Bonn, Germany
[11] Osped San Raffaele, Milan, Italy
[12] Erasmus MC, Rotterdam, Netherlands
[13] Hosp Univ Bellvitge, Barcelona, Spain
[14] Karolinska Univ Hosp, Stockholm, Sweden
[15] Univ Hosp Basel, Basel, Switzerland
[16] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA
关键词
D O I
暂无
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
P20
引用
收藏
页码:21 / 21
页数:1
相关论文
共 50 条
  • [31] EFFICACY AND SAFETY OF THE COMBINATION EFAVIRENZ (EFV), TENOFOVIR (TDF) AND EMTRICITABINE (FTC) ONCE A DAY IN TREATMENT OF NAIVE ADULT PATIENTS WITH HIV-1 INFECTION: A SYSTEMATIC REVIEW
    Rizzoli-Cordoba, A.
    Delgado-Ginebra, I
    VALUE IN HEALTH, 2011, 14 (03) : A114 - A114
  • [32] Associations with HIV-related symptoms and weight change after switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate to bictegravir/emtricitabine/tenofovir alafenamide
    Lowman, E.
    Hardigan, P.
    Unger, N.
    Lee, N.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 75 - 75
  • [33] TENOFOVIR DISOPROXIL FUMARATE (TDF) VERSUS EMTRICITABINE PLUS TDF (FTC/TDF) FOR TREATMENT OF CHRONIC HEPATITIS B (CHB) IN PATIENTS WITH PERSISTENT VIRAL REPLICATION RECEIVING ADEFOVIR DIPIVOXIL
    Berg, T.
    Moller, B.
    Trinh, H.
    Chan, S.
    Marcellin, P.
    Suarcz, E.
    Snow-Lampart, A.
    Oldach, D.
    Sorbel, J.
    Borroto-Esoda, K.
    Frederick, D.
    Rousseau, F.
    JOURNAL OF HEPATOLOGY, 2009, 50 : S328 - S328
  • [34] Metabolic effects of switching to tenofovir alafenamide/emtricitabine/bictegravir (B/F/TAF) from tenofovir difumarate (TDF) or tenofovir alafenamide (TAF) sparing regimens: METABIC study
    Busca, C.
    Ortega, D.
    Martin-Carbonero, L.
    Mican, R.
    Ramos, L.
    Valencia, M.
    Montejano, R.
    Montes, M.
    Diaz-Almiron, M.
    Delgado, A.
    Bernardino, J.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 150 - 151
  • [35] Longer term safety of emtricitabine/tenofovir alafenamide (F/TAF) and emtricitabine/tenofovir disoproxil fumarate (F/TDF) for HIV pre-exposure prophylaxis (PrEP): DISCOVER trial week 96 results
    Ogbuagu, O.
    Podzamczer, D.
    Salazar, L.
    Henry, K.
    Asmuth, D.
    Wohl, D.
    Gilson, R.
    Shao, Y.
    Ebrahimi, R.
    Carter, C.
    Das, M.
    McCallister, S.
    Brunetta, J.
    Kronborg, G.
    Reeves, I.
    Spinner, C.
    HIV MEDICINE, 2020, 21 : 12 - 12
  • [36] COST EFFECTIVENESS ANALYSIS OF THE COMBINATION EFAVIRENZ (EFV), TENOFOVIR (TDF) AND EMTRICITABINE (FTC) ONCE A DAY IN TREATMENT OF NAIVE ADULT PATIENTS WITH HIV INFECTION IN MEXICO
    Rizzoli-Cordoba, A.
    Delgado-Ginebra, I
    Pizarro-Castellanos, M.
    Castillo, J. J.
    VALUE IN HEALTH, 2011, 14 (03) : A119 - A119
  • [37] RENAL TOXICITY FOR SWITCHING FROM TENOFOVIR/EMTRICITABINE (TDF/FTC) TO ABACAVIR/LAMIVUDINE (ABC/3TC): AN ASSOCIATION TO BE CLARIFIED
    Manzini, L.
    Borghi, V.
    Rusconi, S.
    Vergani, B.
    Bonfanti, P.
    Calza, L.
    Narciso, P.
    Lenoci, F.
    Maggi, P.
    Mussini, C.
    INFECTION, 2011, 39 : S66 - S67
  • [38] Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults
    Cohen, Calvin
    Wohl, David
    Arribas, Jose R.
    Henry, Keith
    Van Lunzen, Jan
    Bloch, Mark
    Towner, William
    Wilkins, Edmund
    Ebrahimi, Ramin
    Porter, Danielle
    White, Kirsten
    Walker, Ivan
    Chuck, Susan
    De-Oertel, Shampa
    Fralich, Todd
    AIDS, 2014, 28 (07) : 989 - 997
  • [39] Why Are Patients Switching from Tenofovir Disoproxil Fumarate/Emtricitabine (Truvada) to Tenofovir Alafenamide/Emtricitabine (Descovy) for Pre-Exposure Prophylaxis?
    D'Angelo, Alexa B.
    Westmoreland, Drew A.
    Carneiro, Pedro B.
    Johnson, Jeremiah
    Grov, Christian
    AIDS PATIENT CARE AND STDS, 2021, 35 (08) : 327 - 334
  • [40] Satisfaction and knowledge of patients with HIV after switching from tenofovir to tenofovir alafenamide in regimens containing emtricitabine and rilpivirine
    Velez-Diaz-Pallares, Manuel
    Gramage-Caro, Teresa
    Angel Rodriguez-Sagrado, Miguel
    Montero-Llorente, Beatriz
    Bermejo-Vicedo, Teresa
    BIOMEDICA, 2020, 40